|
Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
Xiaoyuan Xu, Bo Feng, Yujuan Guan, Sujun Zheng, Jifang Sheng, Xingxiang Yang, Yuanji Ma, Yan Huang, Yi Kang, Xiaofeng Wen, Jun Li, Youwen Tan, Qing He, Qing Xie, Maorong Wang, Ping An, Guozhong Gong, Huimin Liu, Qin Ning, Rui Hua, Bo Ning, Wen Xie, Jiming Zhang, Wenxiang Huang, Yongfeng Yang, Minghua Lin, Yingren Zhao, Yanhong Yu, Jidong Jia, Dongliang Yang, Liang Chen, Yinong Ye, Yuemin Nan, Zuojiong Gong, Quan Zhang, Peng Hu, Fusheng Wang, Yongguo Li, Dongliang Li, Zhansheng Jia, Jinlin Hou, Chengwei Chen, Jinzi J. Wu, Lai Wei
Published online: September 30, 2019
doi:10.14218/JCTH.2019.00033
|